Axsome Therapeutics (AXSM) Capital Expenditures Growth (3y) (2018 - 2026)
Axsome Therapeutics (AXSM) Capital Expenditures Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn | 19.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.45% |
| Dec 31, 2025 | -26.80% |
| Sep 30, 2025 | -4.22% |
| Jun 30, 2025 | -62.22% |
| Mar 31, 2025 | 16.46% |
| Dec 31, 2024 | 305.18% |
| Sep 30, 2024 | -29.67% |
| Jun 30, 2024 | 40.18% |
| Mar 31, 2024 | 48.39% |
| Dec 31, 2023 | -29.86% |
| Sep 30, 2023 | 192.37% |
| Jun 30, 2023 | 166.09% |
| Mar 31, 2023 | 167.72% |
| Dec 31, 2022 | 141.38% |
| Sep 30, 2022 | 174.35% |
| Jun 30, 2022 | 121.11% |
| Mar 31, 2022 | 179.19% |
| Dec 31, 2021 | -83.66% |
| Jun 30, 2021 | 30.48% |
| Mar 31, 2021 | 27.20% |